An interventional study of Papilocare vaginal gel in Human Papilloma Virus, Human Papilloma Virus Infection and Cervix Lesion, sponsored by Procare Health Iberia S.L.. Completed at 19 sites in Spain. Open to female participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-02.
Sponsored by Procare Health Iberia S.L. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Papillomavirus Infections with a site in Spain — 6 open to participants now, 8 under way, 1 of them phase 3. Papillomavirus Infections · Spain.
Among the 21 studies in Papillomavirus Infections with a site in Spain, this one is the 9th largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2019, is one of 5 with no phase, and was the 9th registered.
581 studies on the registry are indexed under Papillomavirus Infections; 133 are open to participants now.
Browse Papillomavirus Infections studies →6 of the 21 studies in Papillomavirus Infections with a site in Spain are open now. Recruiting first, the newest first:
Catalysis SL · Sites in Spain
Ages 30–65 · Women only
Talia Sainz Costa · Sites in Spain
Ages 9–18 · Healthy volunteers
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain
Ages 18–79 · Men only
Marengo Therapeutics, Inc. · Sites in Spain, United States, Canada and 1 more country
Ages 18+
Miquel Angel Pavon Ribas · Sites in Spain
Ages 18+ · Women only
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 89 Papillomavirus Infections studies recruiting now, 40 (45%) set no upper age limit and 44 (49%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.
This study: 30 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2019.
This study's enrollment of 164 is below the median of 229 across 406 interventional studies indexed under Papillomavirus Infections.
Median enrollment 182 across the 16 interventional studies, 384 across the 5 observational. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 21 have an industry lead sponsor. The 10 most frequent:
Procare Health Iberia S.L. is the lead sponsor of 12 studies on the registry; 1 is open to participants now.
Procare Health Iberia S.L. has 4 studies filed under Papillomavirus Infections — fewer than ten, so there is no comparison to draw.
3 of the studies in Papillomavirus Infections with a site in Spain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04199689Phase 3Merck Sharp & Dohme LLCEfficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049) | 2027-01-15 |
| NCT05334706Miquel Angel Pavon RibasA Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV) | 2026-12 |
| NCT05592626Marengo Therapeutics, Inc.A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies in Papillomavirus Infections with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase II, exploratory, randomized, open, controlled and parallel groups clinical trial to evaluate the effectiveness of exploratory gel Papilocare in the repair of the cervico-vaginal mucosa with lesions caused by HPV-HR. All the patients included in the study will be randomized (1:1:1:1) in 4 arms.
Phase II, exploratory, randomized, open, controlled and parallel groups clinical trial to evaluate the effectiveness of exploratory gel Papilocare in the repair of the cervico-vaginal mucosa with lesions caused by HPV-HR. All the patients included in the study will be randomized (1:1:1:1) to Arm A (Papilocare schedule A), Arm B (Papilocare schedule B) and Arm C (Papilocare schedule C) Arm D (usual clinical practice-without treatment-).
Selection period of 1 month, followed by randomization and 6 months of treatment followed by a period of another 6 months without treatment.
Patients will visit the site into a total of 5 visits throughout the study. Total study duration: 13 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Arm A: scheme A (21 days / 1 cannula per day + 7 days rest) x 1 month + alternate days up to 6 months (except for menstruation days)
Device: Papilocare vaginal gel
Arm B: scheme B (21 days / 1 cannula per day + 7 days rest) x 3 months + alternate days up to 6 months (except menstruation days)
Device: Papilocare vaginal gel
Arm C: scheme C (21 days / 1 cannula per day + 7 days rest) x 6 months
Device: Papilocare vaginal gel
Arm D: usual clinical practice - no treatment
Papilocare is a gel vaginally administered by a singledose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution
Evaluate the repairment of the cervico-vaginal mucosa with concordant colposcopic image
Evaluate the repairment of the cervico-vaginal mucosa in positive high risk HPV women with a cytological result of squamous atypia of undetermined significance (ASC-US) or low-grade squamous lesion (LSIL) or glandular atypia of undetermined significance (AG-US), with concordant colposcopic image, 6 months after the start of treatment.
Time frame: 6 months
Evaluate the repairment of the cervico-vaginal mucosa with concordant colposcopic image
Evaluate the repairment of the cervico-vaginal mucosa in positive high risk HPV women with a cytological result of squamous atypia of undetermined significance (ASC-US) or low-grade squamous lesion (LSIL) or glandular atypia of undetermined significance (AG-US), with concordant colposcopic image at 3 and 12 months after the start of treatment.
Time frame: 3 and 12 months
Evaluation of reeptielization degree of the cervico-vaginal mucosa by a likert-type scale
A likert-type scale will be used to evaluate the reeptielization degree of the cervico-vaginal mucosa at 3, 6 and 12 months after the start of treatment.
Time frame: 3,6 and 12 months
Presence of HPV at 6 and 12 months after starting treatment.
Percentage of patients with total and partial clearance of HPV measured by genotyping PCR at 6 and 12 months after starting treatment.
Time frame: 6 and 12 months]
Evaluation of vaginal health status by vaginal health index score (Bachmann)
The vaginal health index score (Bachmann) will be used to evaluate vaginal health status at 3, 6 and 12 months from the start of treatment
Time frame: 3,6 and 12 months]
To evaluate the safety and tolerability of Papilocare® gel during the 6 months of treatment and 6 months of follow-up.
Safety and tolerability: incidence, nature and severity of adverse events at 6 months of treatment and 6 months of follow-up period.
Time frame: 6 and 12 months]
To assess the stress received from the patients at 3, 6 and 12 months after starting treatment.
The stress will be assessed on the PSS14 scale (Perceived Stress Scale 14 items) at 3, 6 and 12 months after the starting treatment.
Time frame: 3,6 and 12 months]
Evaluation of the satisfaction of papilocare gel use by a likert-type scale
A likert-type scale will be used to evaluate the satisfaction of papilocare gel use by the patients at 3 and 6 months after the start of treat
Time frame: 3 and 6 months]
Percentage of patients with good therapeutic compliance
Percentage of patients with good adherence to the treatment will be used to evaluate the therapeutic compliance at 3 and 6 months after the start of treatment.
Time frame: 3 and 6 months]
Plan to share: Yes — The PIs from the participant sites gonna received the study protocol and the informed consent form previously to the initiation of the study and every time it occurs an amendment over the protocol, ICF or any other study document. Once the study has finished and the data has been analyzed, the PI's from the sites gonna received the CSR.
Supporting information: Study protocol, Informed consent form, Clinical study report
No publications or documents are linked to this record.
Ran from Sep 2019 to primary completion in Jan 2024, 52 months.
Of 119 interventional studies with no phase under Papillomavirus Infections, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 48. This study's 52 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Procare Health Iberia S.L.